Isoform Selective PI3K-beta Inhibitors |
| |
Authors: | Hong Lin |
| |
Institution: | Regenerative Medicine Discovery Performance Unit, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, PA 19426-0989, U.S.A. |
| |
Abstract: | Although PI3K/AKT has undoubtedly been one of the most important pathways that impact tumorigenesis and proliferation, PI3K‐beta has not been considered as a stand‐alone target for potential cancer treatment until the recent discovery of the key role that PI3K‐beta plays in phosphatase and TENsin homolog (PTEN)‐deficient tumors. Medicinal chemistry efforts from the pharmaceutical industry and academia in the past few years have led to significant advancements in understanding beta isoform selectivity and in the development of a clinical drug candidate. |
| |
Keywords: | phosphatidylinositol 3-kinase PI3K-beta PTEN-deficient selectivity structure-activity relationship |
本文献已被 万方数据 等数据库收录! |
|